Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
| Status: | Archived |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
A 48 Week, Phase II, Open-label, 2-cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-experienced Pediatric Subjects Aged 4 Weeks to <2 Years.
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and
antiviral activity of an investigational regimen including FDA approved HIV drugs in
HIV-infected pediatric subjects, ages 4 weeks to < 2 years old.
A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the
pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV
when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced
pediatric subjects aged 4 weeks to <2 years.
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
updating systems to reflect the change in sponsorship.
We found this trial at
1
site
Click here to add this to my saved trials
